NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

The 12 months 91% OS in the SurVaxM trial seems very similar to the 12 months OS of the blended DCVax-L population as is demonstrated by the first K-M curve of the recent publication. The SurVaxM trial included only patients with gross total resection thus probably handing a slight survival advantage to patients in that trial over patients in the DCVax-L trial. Since we do not have all the exclusion/inclusion criteria and long term survival data of the SurVaxM trial it is impossible at this time to speculate whether this vaccine will compete with DCVax-L.

If one day both vaccines are approved I would venture to speculate whether the two vaccines used in combination would have an additive or even synergistic effect.